Applied Therapeutics (NASDAQ:APLT) Director Joel S. Marcus purchased 150,000 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average price of $10.00 per share, for a total transaction of $1,500,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Applied Therapeutics stock opened at $10.00 on Thursday. Applied Therapeutics has a 1 year low of $7.95 and a 1 year high of $10.25.

COPYRIGHT VIOLATION WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at

About Applied Therapeutics

Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.

Read More: What is insider trading?

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with's FREE daily email newsletter.